Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
201-220 of 653 trials

Roxadustat: Impact on Heart and Metabolism

We are investigating how roxadustat influences glucose and fat metabolism and heart function in participants. This study may help us understand its potential benefits for cardiovascular health.

Risk Factors for Cardiovascular DiseaseMetabolic Syndrome1-2 yearsMonitoring phase (IV)Standard MedicinesCardiologyEndocrinologyInternal Medicine

Hepatocellular Carcinoma: Atezolizumab-Bevacizumab with Bacterial Supplements

We are studying whether adding bacterial supplements to a combination of atezolizumab and bevacizumab helps patients with hepatocellular carcinoma who have not responded to first-line treatment. The trial also looks at the safety of this new approach.

Non-resectable Hepatocellular Carcinoma1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHepatologyOncology

Recurrent Low-Grade Serous Ovarian Cancer: Avutometinib and Defactinib Study

We are studying a new combination therapy for patients with recurrent low-grade serous ovarian cancer to see if it helps them live longer and improves their quality of life compared to standard treatments.

Recurrent Low-Grade Serous Ovarian Cancer1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementGynecology and ObstetricsOncology

Pain Management in Dental Emergencies: Methoxyflurane Study

We are studying whether methoxyflurane can effectively reduce pain and anxiety in adults facing oral emergencies. This trial will help us understand its benefits compared to a placebo.

Dental Pain and Sensation Disorders1-2 yearsConfirmation phase (III)Standard MedicinesGynecology and ObstetricsOtolaryngologyPediatrics

Ovarian Cancer: Niraparib Rechallenge Study

We are studying whether Niraparib can help ovarian cancer patients with oligometastatic progression after surgery live longer without their cancer worsening. The trial will also assess safety and various health indicators.

Ovarian Cancer with Oligometastatic Progression1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Heart Function Study: Dobutamine in ATTRwt Patients

We are investigating how different doses of dobutamine affect heart performance in patients with wild-type transthyretin amyloid cardiomyopathy. The study also looks at the safety of this treatment.

Wild-type Transthyretin Amyloid Cardiomyopathy1-2 yearsEfficacy phase (II)Standard MedicinesCardiologyInternal Medicine

Treatment-Resistant Depression: P-glycoprotein Study

We are investigating how a protein may affect people with treatment-resistant depression using advanced imaging. This study compares P-glycoprotein activity in those who do not respond to treatment with those who do.

Depression1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPsychiatry

Ulcerative Colitis: GS-1427 Study

We are testing a new medication, GS-1427, for adults with moderately to severely active ulcerative colitis. The study aims to see if it can improve symptoms and achieve remission compared to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Metastatic Pancreatic Adenocarcinoma: TTX-030 and Chemotherapy

We are studying if adding TTX-030 and possibly budigalimab to standard chemotherapy helps patients with untreated metastatic pancreatic cancer. This trial aims to evaluate the effectiveness and safety of these combinations.

Metastatic Pancreatic Cancer1-2 yearsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Meningioma Treatment: Everolimus and 177Lu-DOTATATE

We are studying a new combination treatment for patients with grades 2 and 3 refractory meningioma. The goal is to see if this approach can help improve survival and manage tumor growth.

Malignant Meningiomas1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncology

Progressive Pulmonary Fibrosis: Inhaled Pirfenidone Study

We are testing an inhaled medication to see if it helps improve lung function and quality of life for people with Progressive Pulmonary Fibrosis. This study compares the medication to a placebo to assess its effects over time.

Progressive Pulmonary Fibrosis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesPulmonology

Atherosclerotic Cardiovascular Disease: Obicetrapib and Ezetimibe Study

We are testing a new combination therapy for people with atherosclerotic cardiovascular disease to see how it affects coronary plaque and overall heart health. This study aims to understand its safety and effectiveness compared to a placebo.

Atherosclerotic Cardiovascular Disease1-2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCardiologyEndocrinology

Neutropenia: Mavorixafor Study

We are investigating a new medication, mavorixafor, for people with neutropenia who have frequent infections. The study will assess how well it works and its safety compared to a placebo.

Neutropenia1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInfectious DiseasesInternal Medicine

Systemic Lupus Erythematosus: Ianalumab Study

We are evaluating a new medication, ianalumab, for patients with systemic lupus erythematosus to see if it helps improve symptoms and reduce flare-ups compared to a placebo.

Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementRheumatology

Chronic Kidney Disease: Camostat Treatment

We are studying the effects of Camostat on kidney function in patients with chronic kidney disease. The goal is to see if it helps with salt and water balance and blood pressure compared to healthy individuals.

Chronic Kidney Disease with Proteinuria1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineNephrology

Ravulizumab for Children with NMOSD

We are studying the safety and effectiveness of Ravulizumab in children and adolescents with NMOSD. This trial aims to see how it affects their neurological function and overall quality of life.

Neuromyelitis Optica Spectrum Disorder1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Cirrhosis and Portal Hypertension: Metformin Study

We are investigating whether metformin can improve liver blood flow in patients with cirrhosis and portal hypertension. This study will also assess the safety of metformin and its effects on liver health.

Portal Hypertension1-2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesHepatologyInternal Medicine

Allergic Rhinitis: New Immunotherapy for Dust Mite Allergy

We are studying a new treatment for people aged 12 to 65 with allergic rhinitis caused by house dust mites. The trial will evaluate its effectiveness and safety compared to a placebo.

Allergic Rhinitis and Asthma1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesAllergologyInternal Medicine

Lupus Nephritis: Ianalumab Study

We are studying whether ianalumab can improve kidney function in people with active lupus nephritis compared to a placebo. This trial also looks at the safety and tolerability of the treatment.

Lupus Nephritis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNephrologyRheumatology

BRAF V600E Mutated Metastatic Colorectal Cancer: ENCORAFENIB and FOLFIRI

We are studying a combination of ENCORAFENIB and FOLFIRI for patients with BRAF V600E mutated metastatic colorectal cancer that has progressed on previous treatments. The goal is to see if this combination can improve treatment outcomes and safety.

Colorectal Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology